Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CRITICS

Financiado

Cerrado

Towards targeting chemokine receptors CCR7 and CCRL1 to control the crossroads o...

Towards targeting chemokine receptors CCR7 and CCRL1 to control the crossroads of tumor host interactions "Current immunotherapeutic strategies to combat cancer are hampered by the ability of tumors to escape immunity necessitating new mechanistic insights into underlying molecular and cellular processes. Through orchestrating complex... ver más

28/02/2013

UoB

210K€

Presupuesto del proyecto: 210K€

Líder del proyecto

THE UNIVERSITY OF BIRMINGHAM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2013-02-28 No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UoB

0.00€ | Lider

Proyectos interesantes

RTC-2017-6131-1

Medical Technol...

Data Science

823K€ Cerrado

EN_ACTI2NG

Medical Technol...

Data Science

3M€ Cerrado

PRR IN IMMUNOTHERAPY

Medical Technol...

Data Science

100K€ Cerrado

ONCORNET

Medical Technol...

Data Science

4M€ Cerrado

PID2020-114147RB-I00

Medical Technol...

Immunology

121K€ Cerrado

PLEC2022-009337

Medical Technol...

Cancer Research

916K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

THE UNIVERSITY OF BIRMINGHAM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 210K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "Current immunotherapeutic strategies to combat cancer are hampered by the ability of tumors to escape immunity necessitating new mechanistic insights into underlying molecular and cellular processes. Through orchestrating complex cellular moves and determining the positioning of immune cells, chemokines govern both productive immune responses and their silencing. Chemokines signal through classical G-protein coupled receptors (GPCRs) but also bind atypical receptors (ACRs). ACRs modulate chemokine availability and create functional chemokine patterns by either degrading or transporting them. Besides their essential role in tumor immunity, GPCRs can be expressed by the tumor cells themselves and contribute to the formation of metastases, a major cause of death in cancer. Importantly, ACRs are also expressed in tumors but their role in tumor-host interactions is not clear. The aim of this project is to take a comprehensive look at the contribution to tumor-host interactions of a paradigmatic chemokine axis with pleiotropic involvement in induction and suppression of immunity and driving tumor metastasis. We will investigate the roles of CCL19 and CCL21, their GPCR, CCR7, and ACR, CCRL1, in regulating tumor progression and orchestrating anti-tumor immunity and its suppression, including in the setting of experimental tumor immunotherapy. The proposed work will entail studies of transplanted murine tumors with hosts and tumors having modified expression levels of chemokines, their GPCR and ACR as well as using models with disrupted function of specific immune cells. The host provides state of the art facilities and profound immunological expertise, whereas the applicant brings complementary competence in molecular biology and cancer and will be able to synergize in order to reach the research objectives. This work should lead to a better understanding of chemokine-driven tumor-host homeostasis and suggest novel ways to treat cancer and promote anti-tumor immunity."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores